Pomerantz LLP is investigating potential securities fraud claims against Ionis Pharmaceuticals following the failure of its Phase-3 CARDIO-TTransform trial for Wainua, a treatment for amyloid cardiomyopathy developed with AstraZeneca. The trial did not meet its primary endpoint, leading to a 23.9% drop in Ionis's stock price on July 9, 2026. The investigation targets whether Ionis and its executives engaged in unlawful business practices. Investors affected by the stock decline are advised to contact the law firm for possible class action participation.
The U.S. Senate failed to pass the CLARITY Act on September 15, falling short of the 60 votes needed. This delays formal crypto legislation but does not end regulatory progress, as the SEC and CFTC plan to act under their existing authority. These ag...
The Walter Family has refuted recent claims that they are reducing their philanthropic efforts, affirming that their financial commitments to various social and environmental causes remain intact. Mark and Kimbra Walter have donated hundreds of milli...
Ethereum price surged past its $2,550–$2,575 resistance zone on September 20, now using this level as support. The token climbed over 75% from $1,510 to $2,650 in three months, marking its second-best quarterly gain on record. Institutional ETF inflo...
Polymarket, a major player in the prediction market sector, is under investigation by the Commodity Futures Trading Commission (CFTC) after a $10 million attempted fraud was uncovered on its U.S. betting platform. The company reportedly rejected 80% ...
In 2024, the AI power trade, which saw surging interest in stocks of power suppliers and equipment makers, has cooled off since June despite rising earnings and positive guidance. This paradox exists because power remains a critical bottleneck for da...
